The National Cancer Institute Office of Biorepositories and Biospecimen Research (OBBR) and the National Institutes of Health Office of Rare Diseases present the Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science

March 13–14, 2008
Renaissance M Street Hotel
Washington, D.C.

Symposium Goal:
The primary goal of the symposium is to address the significant impact of pre-analytical biospecimen variability on cancer research and molecular medicine. The meeting will feature expert presentations and interactive discussions from a broad range of stakeholders whose work involves biospecimens, including research investigators, clinicians, industry representatives, hospital administrators and patient advocates.

Agenda

Thursday, March 13, 2008

7:30 a.m. - 8:30 a.m.  Registration and Continental Breakfast
8:30 a.m. - 8:45 a.m.  Welcome  
Anna D. Barker, Ph.D.  
Deputy Director  
National Cancer Institute (NCI)  
Director  
Advanced Technologies and Strategic Partnerships

8:45 a.m. - 9:15 a.m.  The Importance of High-Quality Biospecimens to the Research Enterprise  
Carolyn C. Compton, M.D., Ph.D.  
Director, Office of Biorepositories and Biospecimen Research (OBBR)  
Acting Director, Office of Technology and Industrial Relations (OTIR)  
Office of the Director, NCI

9:15 a.m. - 9:30 a.m.  Question-and-Answer Session

9:30 a.m. - 10:00 a.m.  The Role of Biospecimens in Biomarker Research: Challenges and Opportunities  
David F. Ransohoff, M.D.  
Professor of Medicine and Clinical Professor of Epidemiology  
University of North Carolina at Chapel Hill

10:00 a.m. - 10:15 a.m.  Question-and-Answer Session

10:15 a.m. - 10:30 a.m.  Break

10:30 a.m. - 12 noon  Lessons Learned: Effects of Biospecimen Quality on Genomic and Proteomic Research  
Session Chair: Carolyn C. Compton, M.D., Ph.D.  
Director, OBBR  
Acting Director, OTIR  
Office of the Director, NCI

10:30 a.m. - 11:00 a.m.  Pitfalls and Gaps in Research Using Human Biospecimens  
Patrick O. Brown, M.D., Ph.D.
11:00 a.m. - 11:15 a.m.  **Question-and-Answer Session**

11:15 a.m. - 11:45 a.m.  **Critical Pre-Analytical Variables in the Real World of Tissue Procurement**

Lance Liotta, M.D., Ph.D.
University Professor, Life Sciences
Co-Director, Center for Applied Proteomics and Molecular Medicine
George Mason University

11:45 a.m. - 12 noon  **Question-and-Answer Session**

12 noon - 1:15 p.m.  **Hosted Lunch Tables: Meet the Experts**

(Lunch will be available for purchase.)

1:15 p.m. - 2:45 p.m.  **HER2/neu: Lessons Learned From Paired Diagnostics and Therapeutics**

*Session Chair: Elizabeth Hammond, M.D., FCAP*
Professor of Pathology
University of Utah School of Medicine/LDS Hospital

**Presentations and Panel Discussion:**

1:15 p.m. - 1:35 p.m.  **Measurement of HER2**
Daniel F. Hayes, M.D.
Clinical Director, Breast Oncology Program
Professor, University of Michigan Comprehensive Cancer Center

1:35 p.m. - 1:55 p.m.  **Molecular Diversity of Human Breast Cancers**
Dennis J. Slamon, M.D., Ph.D.
Director, Clinical/Translational Research
Jonsson Comprehensive Cancer Center
Professor of Medicine and Chief
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

2:15 p.m. - 2:45 p.m.  **Panel Discussion**

2:45 p.m. - 3:00 p.m.  **Break**

3:00 p.m. - 5:00 p.m.  **Research Advances in Biospecimen Science I**

*Session Chair: Scott Jewell, Ph.D.*
Associate Professor, Department of Pathology,
College of Medicine
The Ohio State University

**The NCI Biospecimen Research Network and Literature Database**

Helen Moore, Ph.D.
Director, Biospecimen Research Network
OBBR, NCI

3:00 p.m. - 3:20 p.m.  **Question-and-Answer Session**
3:30 p.m. - 3:50 p.m.  
**Influence of Cellular Heterogeneity in Carcinoma Specimens for Identification of Clinically Relevant Molecular Signatures**  
*James L. Wittliff, Ph.D., M.D. hc*

Professor of Biochemistry and Molecular Biology  
James Graham Brown Cancer Center  
University of Louisville

3:50 p.m. - 4:00 p.m.  
**Question-and-Answer Session**

4:00 p.m. - 4:20 p.m.  
**Effects of Fixation vs. Tissue Processing on Immunohistochemical Analysis**  
*William E. Grizzle, M.D., Ph.D.*  
Professor, Department of Pathology  
University of Alabama at Birmingham

4:20 p.m. - 4:30 p.m.  
**Question-and-Answer Session**

4:30 p.m. - 4:50 p.m.  
**Proteomic Discovery in Archived Tissue Blocks**  
*Brian M. Balgley, M.D., Ph.D.*  
Chief Technical Officer  
Calibrant Biosystems, Inc.

4:50 p.m. - 5:00 p.m.  
**Question-and-Answer Session**

5:00 p.m. - 5:15 p.m.  
**Day 1 Wrap-Up**  
*Carolyn C. Compton, M.D., Ph.D.*  
Director, OBBR  
Acting Director, OTIR  
Office of the Director, NCI

5:15 p.m. - 7:00 p.m.  
**Poster Session and Reception**  
Poster presenters may begin to set up their posters starting at 4:00 p.m.

---

**Friday, March 14, 2008**

7:30 a.m. - 8:30 a.m.  
**Registration and Continental Breakfast**

8:30 a.m. - 9:00 a.m.  
**Locking in Pre-Analytical and Post-Analytical Performance: Being Pound Wise, Not Penny Foolish**  
*Steve Gutman, M.D.*  
Director  
Office of In Vitro Diagnostic Device Evaluation and Safety (OVID)  
Center for Devices and Radiological Health  
Food and Drug Administration (FDA)

9:00 a.m. - 9:15 a.m.  
**Question-and-Answer Session**

9:15 a.m. - 9:35 a.m.  
**Patients' Perspective on Biospecimen Quality**  
*Paula Kim*  
Chief Executive Officer  
Translating Research Across Communities

9:35 a.m. - 9:45 a.m.  
**Question-and-Answer Session**

9:45 a.m. - 10:00 a.m.  
**Break**

10:00 a.m. - 11:30 a.m.  
**Assessing and Qualifying Biospecimen Quality**  
*Session Chair: Steven Gutman, M.D.*  
Director, OVID, FDA

10:00 a.m. - 10:20 a.m.  
**Signal: Noise? The Importance of the Pre-Analytical Phase in Sample Storage**  
*Scott D. Patterson, Ph.D.*  
Executive Director, Medical Sciences  
Amgen Inc.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20 a.m. - 10:30 a.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-Analytical Variables in Validation of Methylated Biomarkers in Blood Plasma</strong></td>
</tr>
<tr>
<td></td>
<td><em>Theo deVos, Ph.D., M.S.P.H.</em></td>
</tr>
<tr>
<td></td>
<td>Vice President, Development Diagnostics</td>
</tr>
<tr>
<td></td>
<td>Epigenomics, Inc.</td>
</tr>
<tr>
<td>10:30 a.m. - 10:50 a.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-Analytical Variables in Validation of Methylated Biomarkers in Blood Plasma</strong></td>
</tr>
<tr>
<td></td>
<td><em>Theo deVos, Ph.D., M.S.P.H.</em></td>
</tr>
<tr>
<td></td>
<td>Vice President, Development Diagnostics</td>
</tr>
<tr>
<td></td>
<td>Epigenomics, Inc.</td>
</tr>
<tr>
<td>10:50 a.m. - 11:00 a.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td>11:00 a.m. - 11:20 a.m.</td>
<td><strong>Measuring Biomarker Stability in Frozen Tissue</strong></td>
</tr>
<tr>
<td></td>
<td><em>Scott Jewell, Ph.D.</em></td>
</tr>
<tr>
<td></td>
<td>Associate Professor, Department of Pathology</td>
</tr>
<tr>
<td></td>
<td>College of Medicine</td>
</tr>
<tr>
<td></td>
<td>The Ohio State University</td>
</tr>
<tr>
<td>11:20 a.m. - 11:30 a.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td>11:30 a.m. - 12:30 p.m.</td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td></td>
<td><em>(Lunch will be available for purchase.)</em></td>
</tr>
<tr>
<td>12:30 p.m. - 2:00 p.m.</td>
<td><strong>Research Advances in Biospecimen Science II</strong></td>
</tr>
<tr>
<td></td>
<td><em>Session Chair: William Grizzle, M.D., Ph.D.</em></td>
</tr>
<tr>
<td></td>
<td>Professor, Department of Pathology</td>
</tr>
<tr>
<td></td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>12:30 p.m. - 12:50 p.m.</td>
<td><strong>Overcoming Challenges to Tissue-Based Studies</strong></td>
</tr>
<tr>
<td></td>
<td><em>Christopher J. Logothetis, M.D.</em></td>
</tr>
<tr>
<td></td>
<td>Chair, Department of Genitourinary Medical Oncology,</td>
</tr>
<tr>
<td></td>
<td>The University of Texas M. D. Anderson Cancer Center</td>
</tr>
<tr>
<td>12:50 p.m. - 1:00 p.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td>1:00 p.m. - 1:20 p.m.</td>
<td><strong>Nonpatient-Related Variables Affecting Detection of VEGF in Urine Biospecimens</strong></td>
</tr>
<tr>
<td></td>
<td><em>Kevin Camphausen, M.D.</em></td>
</tr>
<tr>
<td></td>
<td>Chief, Radiation Oncology Branch</td>
</tr>
<tr>
<td></td>
<td>Head, Imaging and Molecular Therapeutics Section</td>
</tr>
<tr>
<td></td>
<td>NCI</td>
</tr>
<tr>
<td>1:20 p.m. - 1:30 p.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td>1:30 p.m. - 1:50 p.m.</td>
<td><strong>Defining Optimal Tissue Handling Procedures for Multiplex In Vitro Diagnostics</strong></td>
</tr>
<tr>
<td></td>
<td><em>Guido Brink, M.S.</em></td>
</tr>
<tr>
<td></td>
<td>Director, Quality Management and Regulatory Affairs</td>
</tr>
<tr>
<td></td>
<td>Agenda, BV</td>
</tr>
<tr>
<td>1:50 p.m. - 2:00 p.m.</td>
<td><strong>Question-and-Answer Session</strong></td>
</tr>
<tr>
<td>2:00 p.m. - 2:15 p.m.</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>2:15 p.m. - 3:45 p.m.</td>
<td><strong>Incorporating Biospecimen Science Into Research Practice: Opportunities, Challenges, and Progress</strong></td>
</tr>
<tr>
<td></td>
<td><em>Session Chair: Kevin Camphausen, M.D.</em></td>
</tr>
<tr>
<td></td>
<td>Head, Imaging and Molecular Therapeutics Section</td>
</tr>
<tr>
<td></td>
<td>Chief, Radiation Oncology Branch</td>
</tr>
<tr>
<td></td>
<td>NCI</td>
</tr>
<tr>
<td>2:15 p.m. - 2:35 p.m.</td>
<td><strong>Harmonizing Biospecimen Best Practices Across the Prostate SPORES</strong></td>
</tr>
<tr>
<td></td>
<td><em>Angelo M. De Marzo M.D., Ph.D.</em></td>
</tr>
<tr>
<td></td>
<td>Director, Tissue Microarray Core Facility</td>
</tr>
<tr>
<td></td>
<td>Associate Director of Cancer Research Pathology</td>
</tr>
<tr>
<td></td>
<td>Associate Professor of Pathology, Oncology, and Urology</td>
</tr>
</tbody>
</table>
2:35 p.m. - 2:45 p.m.  Question-and-Answer Session
2:45 p.m. - 3:05 p.m.  Practical Applications of Biospecimen Science in Biobanking
   Gerry Thomas, Ph.D.
   Professor of Molecular Pathology
   Imperial College London
3:05 p.m. - 3:15 p.m.  Question-and-Answer Session
3:15 p.m. - 3:35 p.m.  CAP: Preparing Pathologists
   Elizabeth Hammond, M.D., FCAP
   Professor of Pathology
   University of Utah School of Medicine/LDS Hospital
3:35 p.m. - 3:45 p.m.  Question-and-Answer Session
3:45 p.m. - 4:15 p.m.  General Question-and-Answer Session
4:15 p.m. - 4:30 p.m.  Closing Remarks
   Carolyn C. Compton, M.D., Ph.D.
   Director, OBBR
   Acting Director, OTIR
   Office of the Director, NCI